News Release

Responding to Ethics Concerns, Good Gov. Groups Urge Delay on Price Vote

Letter urges Senate to delay Price vote until SEC can investigate ethics violations
For Immediate Release

WASHINGTON, DC – Following reports of privileged and discounted stock trading by Rep. Tom Price (GA-06), good government groups joined together Tuesday urging the Senate to delay any vote on Mr. Price’s nomination for Secretary of Health and Human Services (HHS). In a letter to Sens. Mitch McConnell and Chuck Schumer, advocates urged Senate leadership to delay voting on Mr. Price’s nomination until the Securities and Exchange Commission (SEC) has had the opportunity to fully investigate potential violations of the law.

Signers include Center for Media and Democracy, Citizens for Responsibility and Ethics in Washington (CREW), Common Cause, CREDO, Democracy 21, Democracy Matters, End Citizens United, Every Voice, Free Speech for People, Money Out Voters In, Public Citizen, Represent.Us, the Rootstrikers Project at Demand Progress, and the U.S. Public Interest Research Group (PIRG).

Read the full letter to Senate leadership here.

“We know that Mr. Price accepted privileged, discounted investments related to his work as a member of Congress,” said Andre Delattre, Executive Director of U.S. PIRG. “Now the public deserves to know whether Mr. Price broke the law. Using your elected position to cheat the stock market isn’t a joke – it’s a federal offense. Before the Senate rushes to confirm a nominee for the president’s cabinet, the public deserves to know whether they’re guilty of insider trading. Mr. Price was a sitting Member of Congress actively working to pass health policy changes - to accept special stock offers from a healthcare company in that position was not ethical and not appropriate.”

As a public interest advocacy group, U.S. PIRG supported the 2012 passage of the STOCK Act, legislation which strengthened prohibitions against Members of Congress engaging in insider trading. Lawmakers are now requesting that the SEC investigate Mr. Price’s discounted investments in Innate Immunotherapeutics Ltd.

Mr. Price received stocks at a 12% discounted rate over other investors following a tip from a fellow member of Congress that Innate Immunotherapeutics Ltd. was holding a private placement offering. Mr. Price was one of fewer than 20 U.S. investors invited to participate in the offering, through which he purchased 400,613 shares at a discounted rate, making an immediate profit in the tens of thousands of dollars.

In addition to specifying that it is against the law for Members of Congress to trade on non-public information gleaned through the course of official business, the STOCK Act also creates an important system of real-time transparency of stock trading activity by members and staff. Under the law, lawmakers and congressional candidates, the president and vice president, members of the cabinet and high-ranking congressional and executive branch staff are required to file personal financial disclosure statements each year which are published online.

###

U.S. PIRG, the U.S. Public Interest Research Group, is a consumer group that stands up to powerful interests whenever they threaten our health and safety, our financial security, or our right to fully participate in our democratic society.

Priority Action

We're calling on big restaurant chains to stop the overuse of antibiotics on factory farms. Tell KFC to stop serving meat raised on routine antibiotics.

Support Us

Your donation supports U.S. PIRG’s work to stand up for consumers on the issues that matter, especially when powerful interests are blocking progress.

Consumer Alerts

Join our network and stay up to date on our campaigns, get important consumer updates and take action on critical issues.
Optional Member Code